Attached files
| file | filename |
|---|---|
| EXCEL - IDEA: XBRL DOCUMENT - Protalix BioTherapeutics, Inc. | Financial_Report.xls |
| EX-32.1 - EXHIBIT 32.1 - Protalix BioTherapeutics, Inc. | v303493_ex32-1.htm |
| EX-31.1 - EXHIBIT 31.1 - Protalix BioTherapeutics, Inc. | v303493_ex31-1.htm |
| EX-31.2 - EXHIBIT 31.2 - Protalix BioTherapeutics, Inc. | v303493_ex31-2.htm |
| EX-32.2 - EXHIBIT 32.2 - Protalix BioTherapeutics, Inc. | v303493_ex32-2.htm |
| 10-K - Protalix BioTherapeutics, Inc. | v303493_10k.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statement on Form S-3 (No. 333-171615) and Registration Statement on Form S-8 (No. 333-148983) of Protalix BioTherapeutics, Inc. of our report dated February 27, 2012 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 10-K.
| /s/ Kesselman & Kesselman |
| Kesselman & Kesselman |
| Certified Public Accountants (lsr.) |
| A member firm of PricewaterhouseCoopers International Limited |
Tel-Aviv, Israel
February 27, 2012
Kesselman & Kesselman, Trade Tower, 25 Hamered Street, Tel-Aviv 68125, Israel, P.O Box 452 Tel-Aviv 61003 Telephone: +972 -3- 7954555, Fax:+972 -3- 7954556, www.pwc.co.il